Report overview
The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.
Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.
This report aims to provide a comprehensive presentation of the global market for Drugs for Vulvovaginal Candidiasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Vulvovaginal Candidiasis. This report contains market size and forecasts of Drugs for Vulvovaginal Candidiasis in global, including the following market information:
Global Drugs for Vulvovaginal Candidiasis Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Drugs for Vulvovaginal Candidiasis Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Drugs for Vulvovaginal Candidiasis companies in 2022 (%)
The global Drugs for Vulvovaginal Candidiasis market was valued at US$ 840.2 million in 2022 and is projected to reach US$ 928.4 million by 2029, at a CAGR of 1.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The main manufacturers of Drugs for Vulvovaginal Candidiasis are Bayer, J & J, Pfizer, Perrigo, Effik, etc. The top three manufacturers in the world occupy about 40% of the market share.
The Asia-Pacific region is the world's largest market, with a market share of about 45%, followed by North America with nearly 20%
We surveyed the Drugs for Vulvovaginal Candidiasis manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Drugs for Vulvovaginal Candidiasis Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Vulvovaginal Candidiasis Market Segment Percentages, by Type, 2022 (%)
Cream
Pessary
Other
Global Drugs for Vulvovaginal Candidiasis Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Vulvovaginal Candidiasis Market Segment Percentages, by Application, 2022 (%)
Hospital & Clinic
Pharmacy
Global Drugs for Vulvovaginal Candidiasis Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Drugs for Vulvovaginal Candidiasis Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Drugs for Vulvovaginal Candidiasis revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Drugs for Vulvovaginal Candidiasis revenues share in global market, 2022 (%)
Key companies Drugs for Vulvovaginal Candidiasis sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Drugs for Vulvovaginal Candidiasis sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Bayer
Perrigo
J & J
Pfizer
Bristol-Myers Squibb
Effik
Teva
Sanofi
Cisen Pharmaceutical
Kingyork Group
Outline of Major Chapters:
Chapter 1: Introduces the definition of Drugs for Vulvovaginal Candidiasis, market overview.
Chapter 2: Global Drugs for Vulvovaginal Candidiasis market size in revenue and volume.
Chapter 3: Detailed analysis of Drugs for Vulvovaginal Candidiasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Drugs for Vulvovaginal Candidiasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Drugs for Vulvovaginal Candidiasis capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
